NRSN Stock Overview
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases.
NeuroSense Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.74|
|52 Week High||US$8.18|
|52 Week Low||US$1.23|
|1 Month Change||83.89%|
|3 Month Change||-30.98%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-32.18%|
Recent News & Updates
Is NeuroSense Stock A Buy, Sell, Or Hold After Jumping Up In March?
NRSN is a clinical-stage biotech developing therapeutics for neurodegenerative diseases, including ALS. The company's "PrimeC" drug candidate has shown promising efficacy results and is expected to start a Phase 2b. The stock looks interesting considering the opportunity and several expected catalysts through 2022.
|NRSN||US Biotechs||US Market|
Return vs Industry: Insufficient data to determine how NRSN performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how NRSN performed against the US Market.
|NRSN Average Weekly Movement||18.7%|
|Biotechs Industry Average Movement||13.1%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: NRSN is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.
Volatility Over Time: NRSN's weekly volatility has decreased from 62% to 19% over the past year, but is still higher than 75% of US stocks.
About the Company
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company’s preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer’s disease.
NeuroSense Therapeutics Fundamentals Summary
|NRSN fundamental statistics|
Is NRSN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NRSN income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.40|
|Net Profit Margin||0.00%|
How did NRSN perform over the long term?See historical performance and comparison
Is NRSN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NRSN?
Other financial metrics that can be useful for relative valuation.
|What is NRSN's n/a Ratio?|
Price to Book Ratio vs Peers
How does NRSN's PB Ratio compare to its peers?
|NRSN PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
SLNO Soleno Therapeutics
SBFM Sunshine Biopharma
FBRX Forte Biosciences
NRSN NeuroSense Therapeutics
Price-To-Book vs Peers: NRSN is expensive based on its Price-To-Book Ratio (2.6x) compared to the peer average (0.8x).
Price to Earnings Ratio vs Industry
How does NRSN's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: NRSN is expensive based on its Price-To-Book Ratio (2.6x) compared to the US Biotechs industry average (1.6x)
Price to Book Ratio vs Fair Ratio
What is NRSN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||2.6x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate NRSN's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of NRSN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate NRSN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate NRSN's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NRSN's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is NeuroSense Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NRSN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NRSN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NRSN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NRSN is forecast to have no revenue next year.
High Growth Revenue: NRSN is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NRSN's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has NeuroSense Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: NRSN is currently unprofitable.
Growing Profit Margin: NRSN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if NRSN's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare NRSN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NRSN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: NRSN has a negative Return on Equity (-38.26%), as it is currently unprofitable.
Discover strong past performing companies
How is NeuroSense Therapeutics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: NRSN's short term assets ($14.0M) exceed its short term liabilities ($1.2M).
Long Term Liabilities: NRSN's short term assets ($14.0M) exceed its long term liabilities ($1.0M).
Debt to Equity History and Analysis
Debt Level: NRSN is debt free.
Reducing Debt: NRSN has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NRSN has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: NRSN has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 42.9% each year.
Discover healthy companies
What is NeuroSense Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NRSN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NRSN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NRSN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NRSN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as NRSN has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Alon Ben-Noon (42 yo)
Mr. Alon Ben-Noon is the Co-Founder of NeuroSense Therapeutics Ltd. and serves as its Chief Executive Officer since 2016 and Director since February 2017. Mr. Ben-Noon served as Chair of Board of Directors...
Experienced Management: NRSN's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Experienced Board: NRSN's board of directors are not considered experienced ( 0.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: NRSN only recently listed within the past 12 months.
NeuroSense Therapeutics Ltd.'s employee growth, exchange listings and data sources
- Name: NeuroSense Therapeutics Ltd.
- Ticker: NRSN
- Exchange: NasdaqCM
- Founded: 2017
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$31.987m
- Shares outstanding: 11.67m
- Website: https://www.neurosense-tx.com
Number of Employees
- NeuroSense Therapeutics Ltd.
- Building B
- 11 HaMenofim Street
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/29 00:00|
|End of Day Share Price||2022/06/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.